{"id":1714,"date":"2023-06-25T17:32:51","date_gmt":"2023-06-25T17:32:51","guid":{"rendered":"https:\/\/kidneydiseaseclinic.net\/kdc\/cefuroxime\/"},"modified":"2023-06-25T19:41:08","modified_gmt":"2023-06-25T19:41:08","slug":"cefuroxime","status":"publish","type":"post","link":"https:\/\/kidneydiseaseclinic.net\/kdc\/cefuroxime\/","title":{"rendered":"Cefuroxime"},"content":{"rendered":"

<\/p>\n

Cefuroxime oral<\/h1>\n

CLINICAL USE<\/h3>\n

Antibacterial agent<\/p>\n

DOSE IN NORMAL RENAL FUNCTION<\/h3>\n

125\u2013500 mg every 12 hoursGonorrhoea: single dose of 1 g<\/p>\n

PHARMACOKINETICS<\/h3>\n
  • Molecular weight                           :510.5 (as axetil)<\/li>\n
  • %Protein binding                           :50<\/li>\n
  • %Excreted unchanged in urine     : 85\u201390<\/li>\n
  • Volume of distribution (L\/kg)       :0.13\u20131.8<\/li>\n
  • half-life \u2013 normal\/ESRD (hrs)      :1.2\/17
    \n

    DOSE IN RENAL IMPAIRMENT<\/h3>\n

    GFR (mL\/MIN)<\/h4>\n<\/li>\n
  • 20 to 50     : Dose as in normal renal function<\/li>\n
  • 10 to 20     : Dose as in normal renal function<\/li>\n
  • <10           : Dose as in normal renal function
    \n

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES<\/h3>\n<\/li>\n
  • CAPD                :Dialysed. Dose as in normal renal function<\/li>\n
  • HD                     :Dialysed. Dose as in normal renal function<\/li>\n
  • HDF\/high flux   :Dialysed. Dose as in normal renal function<\/li>\n
  • CAV\/VVHD      :Dialysed. Dose as in normal renal function
    \n

    IMPORTANT DRUG INTERACTIONS<\/h3>\n

    Potentially hazardous interactions with other drugsAnticoagulants: effects of coumarins may be enhanced<\/p>\n

    ADMINISTRATION<\/h3>\n

    Reconstition<\/h4>\n

    Route<\/h4>\n

    Oral<\/p>\n

    Rate of Administration<\/h4>\n

    \u2013<\/p>\n

    Comments<\/h4>\n

    Take with or after food .134 CEFUroXiME (PArEnTErAL)<\/p>\n

    CLINICAL USE<\/h3>\n

    Antibacterial agent<\/p>\n

    DOSE IN NORMAL RENAL FUNCTION<\/h3>\n

    750 mg \u2013 1.5 g every 6\u20138 hoursMeningitis: 3 g every 8 hours<\/p>\n

    PHARMACOKINETICS<\/h3>\n<\/li>\n
  • Molecular weight                           :446.4 (as sodium salt)<\/li>\n
  • %Protein binding                           :50<\/li>\n
  • %Excreted unchanged in urine     : 85\u201390<\/li>\n
  • Volume of distribution (L\/kg)       :0.13\u20131.8<\/li>\n
  • half-life \u2013 normal\/ESRD (hrs)      :1.2\/17
    \n

    DOSE IN RENAL IMPAIRMENT<\/h3>\n

    GFR (mL\/MIN)<\/h4>\n<\/li>\n
  • 20 to 50     : 750 mg \u2013 1.5 g every 8 hours<\/li>\n
  • 10 to 20     : 750 mg \u2013 1.5 g every 8\u201312 hours<\/li>\n
  • <10           : 750 mg \u2013 1.5 g every 12\u201324 hours
    \n

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES<\/h3>\n<\/li>\n
  • CAPD                :dialysed. Dose as in GFR<\/li>\n
  • <10           : mL\/min<\/li>\n
  • HD                     :Dialysed. Dose as in GFR<\/li>\n
  • <10           : mL\/min<\/li>\n
  • HDF\/high flux   :Dialysed. Dose as in GFR<\/li>\n
  • <10           : mL\/min<\/li>\n
  • CAV\/VVHD      :Dialysed. Dose as in GFR=10\u201320 mL\/min
    \n

    IMPORTANT DRUG INTERACTIONS<\/h3>\n

    Potentially hazardous interactions with other drugsAnticoagulants: effects of coumarins may be enhanced<\/p>\n

    ADMINISTRATION<\/h3>\n

    Reconstition<\/h4>\n

    IM: 1 mL of water for injection to each 250 mgIV bolus: 2 mL of water for injection to each 250 mg, but 15 mL of water for injection to 1.5 g<\/p>\n

    IV infusion<\/h4>\n

    : 1.5 g in 50 mL of water for injection<\/p>\n

    Route<\/h4>\n

    IM, IV<\/p>\n

    Rate of Administration<\/h4>\n

    IV bolus: over 3\u20135 minutes<\/p>\n

    IV infusion<\/h4>\n

    : over 30 minutes<\/p>\n

    Comments<\/h4>\n

    Do not mix in syringe with aminoglycoside antibioticsInjection may also be reconstituted with: sodium chloride 0.9%, glucose 5%, glucose saline, Hartmann\u2019s solutionCefuroxime and metronidazole can be mixed (see manufacturer\u2019s guidelines)<\/p>\n

    OTHER INFORMATION<\/h4>\n

    At high doses, take care in patients receiving concurrent treatment with potent diuretics such as furosemide, or aminoglycosides, as combination can adversely affect renal functionEach 750 mg vial \u2261 1.8 mmol sodiumCefuroxime (parenteral).<\/li>\n","protected":false},"excerpt":{"rendered":"

    Cefuroxime oral CLINICAL USE Antibacterial agent DOSE IN NORMAL RENAL<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[7],"class_list":["post-1714","post","type-post","status-publish","format-standard","hentry","category-blog","tag-post-by-auto-php"],"_links":{"self":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/1714","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/comments?post=1714"}],"version-history":[{"count":1,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/1714\/revisions"}],"predecessor-version":[{"id":2833,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/1714\/revisions\/2833"}],"wp:attachment":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/media?parent=1714"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/categories?post=1714"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/tags?post=1714"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}